Trial Profile
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Iodine radioactive
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms IIT Sutent
- 24 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 28 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Mar 2014 Planned number of patients changed from 46 to 35 as reported by ClinicalTrials.gov.